China SXT Pharmaceuticals Inc (SXTC)
NASDAQ:SXTC
SXTC Stock Chart & Stats
$2.01
-$0.06(-11.09%)
At close: 4:00 PM EST
$2.01
-$0.06(-11.09%)
Day’s Range― - ―
52-Week Range$1.25 - $1,046.85
Previous CloseN/A
Volume317.99K
Average Volume (3M)289.38K
Market Cap
$86.37M
Enterprise Value-$18.67M
Total Cash (Recent Filing)$18.10M
Total Debt (Recent Filing)$983.88K
Price to Earnings (P/E)―
Beta0.92
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding38,218,080
10 Day Avg. Volume19,389
30 Day Avg. Volume289,385
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)9.79
Price to Sales (P/S)86.83
P/FCF Ratio-64.40
Enterprise Value/Market Cap-0.22
Enterprise Value/Revenue-10.73
Enterprise Value/Gross Profit-50.82
Enterprise Value/Ebitda7.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China SXT Pharmaceuticals News
SXTC FAQ
What was China SXT Pharmaceuticals Inc’s price range in the past 12 months?
China SXT Pharmaceuticals Inc lowest stock price was $1.25 and its highest was $1046.85 in the past 12 months.
What is China SXT Pharmaceuticals Inc’s market cap?
China SXT Pharmaceuticals Inc’s market cap is $86.37M.
When is China SXT Pharmaceuticals Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were China SXT Pharmaceuticals Inc’s earnings last quarter?
Currently, no data Available
Is China SXT Pharmaceuticals Inc overvalued?
According to Wall Street analysts China SXT Pharmaceuticals Inc’s price is currently Overvalued.
Does China SXT Pharmaceuticals Inc pay dividends?
China SXT Pharmaceuticals Inc does not currently pay dividends.
What is China SXT Pharmaceuticals Inc’s EPS estimate?
China SXT Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China SXT Pharmaceuticals Inc have?
China SXT Pharmaceuticals Inc has 38,218,080 shares outstanding.
What happened to China SXT Pharmaceuticals Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of China SXT Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in SXTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China SXT Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.39%
12-Months-Change
Fundamentals
Return on Equity
-14.68%
Trailing 12-Months
Asset Growth
-14.98%
Trailing 12-Months
Company Description
China SXT Pharmaceuticals Inc
Established in 2005 and headquartered in Taizhou, China, China SXT Pharmaceuticals, Inc. operates as a pharmaceutical company with a comprehensive focus on traditional Chinese medicine pieces (TCMP). Its activities span the entire process, from research and development to the production, marketing, and distribution of these products across China. The company's offerings include a range of TCMP products categorized as advanced, fine, or regular, alongside a wide assortment of raw medicinal materials. Examples of these raw materials include SanQiFen, HongQi, SuMu, JiangXiang, and numerous others like ChuanBeiMu, RenShen, and JueMingZi. These products are sold under recognized brand names such as Suxuantang, Hui Chun Tang, and Tong Ren Tang. China SXT Pharmaceuticals distributes its goods to a diverse clientele, including other pharmaceutical companies, various chain pharmacies, hospitals, and specialized pharmaceutical distributors.
Technical Analysis
China Pharma Holdings
―
Prophase Labs
―
TherapeuticsMD
―
Cumberland Pharmaceuticals
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.20% Other Institutional Investors
99.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---